🇺🇸 FDA
Patent

US 10561662

4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139

granted A61KA61K31/53A61P

Quick answer

US patent 10561662 (4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139) held by Takeda Pharmaceutical Company Limited expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Feb 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
32
CPC classes
A61K, A61K31/53, A61P, A61P21/00, A61P25/00